There is one clinical trial.
This is a randomized, double-blind, placebo-controlled, in which one dose of nangibotide will be tested versus placebo. All patients with a diagnosis of coronavirus disease 2019 (COVID-19), and a requirement for invasive mechanical ventilation will be considered for study participation. All study patients will receive standard of care treatment throughout the study. After screening for eligibility, patients will be randomized to one of two treatment arms. Patients will receive a continuous intravenous (i.v.) infusion of nangibotide at 1.0 mg/kg/h or a matching placebo. Treatment with study drug must be initiated as early as possible but no later than 48 hours after the initiation of invasive mechanical ventilation. Patients will be treated for 5 days or until discharge from critical care, whichever is sooner. The treatment with study drug will be in addition to standard of care. A follow-up visit will be performed on days 8 and 14. The end of study visit is at day 28.
Description: Incidence of adverse events until day 28Measure: Adverse Events Time: 28 days
Description: Incidence of mortality until day 28Measure: Mortality Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports